PEG 3350の世界市場：製品タイプ・年齢・用途・流通チャンネル・地域別の予測 (～2032年)

PEG 3350の市場規模は、2023年の19億2,000万米ドル、2024年の20億8,000万米ドルから、予測期間中は6.63%のCAGRで推移し、2032年には37億1,000万米ドルの規模に成長すると予測されています。市場成長の原動力となっているのは、インドやその他の新興国市場における大腸癌の有病率の増加、戦略的イニシアチブの増加、座りがちなライフスタイルや運動不足の増加です。

大腸癌は世界規模で増加しつつあります。例えば、Lancet Regional Health Southeast Asiaの論文によれば、インドでは大腸癌は7番目に罹患率の高い癌であり、2021年には65,358人が新たに罹患します。大腸癌の世界の罹患率は上昇傾向にあり、現在の罹患率は人口10万人あたり19.5人で、インドでは15.2人です。また、カロリーが高く食物繊維の少ない食事、赤身肉や加工食品の過剰摂取、運動不足など、ライフスタイルの進化も背景にあります。さらに、インドにおける大腸癌の年齢性別調整率は20.6％増加しており、50歳未満の成人の数が大幅に増加しています。

これらのことから、PEG 3350の需要は大腸癌の有病率の増加に対応して増加すると予想されます。PEG 3350市場は、大腸癌の累積有病率に加え、予測期間中のアルコールやタバコ製品の消費量の増加、喫煙率の上昇、食生活の乱れなどの生活習慣の変化によっても牽引されると予測されています。

地域別展望

2022年、北米のPEG 3350市場がもっとも高い市場シェアを占めました。これは、北米地域で大腸癌や糖尿病、癌、神経障害を含む他の疾患の有病率が増加している結果です。

欧州市場は2番目に高いシェアを示しており、これは大腸癌の有病率の増加や地域全体で座りがちなライフスタイルの採用の増加に起因しています。さらに、ドイツのPEG 3350市場は最大の市場シェアとして特定されとぉり、欧州地域で最も急成長している市場になる見通しです。

アジア太平洋地域の市場は、2024年から2032年にかけて大きく成長すると予想されています。これは、同地域における大腸癌の有病率の増加、座りがちなライフスタイルや運動不足、高齢者人口の増加の結果です。国別では、中国が最も高いシェアを持ち、インドがそれに続くと予想されています。

当レポートでは、世界のPEG 3350の市場を調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 概要
• 促進要因
  • インドおよびその他の途上国における大腸癌の罹患率の上昇
  • 戦略的取り組みの増加
  • 座りがちな生活習慣と運動不足の増加
• 抑制要因
  • PEGに関連する副作用
  • オーガニック代替品への嗜好の高まり
• 機会
  • 新興国市場への参入

第5章 市場要因分析

• バリューチェーン分析
• ポーターのファイブフォース分析
• COVID-19が世界のPEG 3350市場に与える影響

第6章 世界のPEG 3350市場：製品タイプ別

• 概要
• 粉末
• 腸の前処理キット

第7章 世界のPEG 3350市場：年齢別

• 概要
• 小児
• 成人
• 高齢者

第8章 世界のPEG 3350市場：用途別

• 概要
• 便秘
• 医療検査
  • 大腸内視鏡検査
  • バリウム注腸X線検査
• 手術

第9章 世界のPEG 3350市場：流通チャネル別

• 概要
• オンライン薬局
• オフライン薬局

第10章 世界のPEG 3350市場：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第11章 競合情勢

• 概要
• 競合ベンチマーキング
• 世界のPEG 3350市場における主要な成長戦略
• 世界のPEG 3350市場における開発件数でトップの企業
• 主な展開と成長戦略

第12章 企業プロファイル

• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• LGM PHARMA
• MCKESSON CORPORATION
• SISCO RESEARCH LABORATORIES PVT. LTD.
• BASF SE
• MERCK KGAA
• BAYER AG
• LUPIN PHARMACEUTICALS, INC.
• BRECKENRIDGE PHARMACEUTICAL, INC.
• PENDOPHARM

第13章 付録

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
• TABLE 3 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 4 GLOBAL PEG 3350 MARKET, FOR POWDER, BY REGION, 2019-2032 (USD BILLION)
• TABLE 5 GLOBAL PEG 3350 MARKET, FOR BOWEL PREPARATION KIT, BY REGION, 2019-2032 (USD BILLION)
• TABLE 6 GLOBAL PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 7 GLOBAL PEG 3350 MARKET, FOR PEDIATRIC, BY REGION, 2019-2032 (USD BILLION)
• TABLE 8 GLOBAL PEG 3350 MARKET, FOR ADULT, BY REGION, 2019-2032 (USD BILLION)
• TABLE 9 GLOBAL PEG 3350 MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD BILLION)
• TABLE 10 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 11 GLOBAL PEG 3350 MARKET, FOR CONSTIPATION, BY REGION, 2019-2032 (USD BILLION)
• TABLE 12 GLOBAL PEG 3350 MARKET, FOR MEDICAL TESTS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 13 GLOBAL PEG 3350 MARKET, FOR COLONOSCOPY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 14 GLOBAL PEG 3350 MARKET, FOR BARIUM ENEMA X-RAY EXAMINATION, BY REGION, 2019-2032 (USD BILLION)
• TABLE 15 GLOBAL PEG 3350 MARKET, FOR SURGERY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 16 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 17 GLOBAL PEG 3350 MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 18 GLOBAL PEG 3350 MARKET, FOR OFFLINE PHARMACY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 19 GLOBAL: PEG 3350 MARKET, BY REGION, 2019-2032 (USD BILLION)
• TABLE 20 NORTH AMERICA: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 21 NORTH AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 22 NORTH AMERICA: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 23 NORTH AMERICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 24 NORTH AMERICA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 25 NORTH AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 26 US: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 27 US: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 28 US: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 29 US: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 30 US: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 31 CANADA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 32 CANADA: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 33 CANADA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 34 CANADA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 35 CANADA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 36 EUROPE: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 37 EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 38 EUROPE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 39 EUROPE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 40 EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 41 EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 42 GERMANY: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 43 GERMANY: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 44 GERMANY: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 45 GERMANY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 46 GERMANY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 47 FRANCE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 48 FRANCE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 49 FRANCE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 50 FRANCE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 51 FRANCE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 52 UK: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 53 UK: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 54 UK: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 55 UK: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 56 UK: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 57 ITALY: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 58 ITALY: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 59 ITALY: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 60 ITALY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 61 ITALY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 62 SPAIN: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 63 SPAIN: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 64 SPAIN: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 65 SPAIN: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 66 SPAIN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 67 REST OF EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 68 REST OF EUROPE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 69 REST OF EUROPE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 70 REST OF EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 71 REST OF EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 72 ASIA-PACIFIC: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 73 ASIA-PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 74 ASIA-PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 75 ASIA-PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 76 ASIA-PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 77 ASIA-PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 78 CHINA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 79 CHINA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 80 CHINA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 81 CHINA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 82 CHINA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 83 INDIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 84 INDIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 85 INDIA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 86 INDIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 87 INDIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 88 JAPAN: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 89 JAPAN: PEG 3350 MARKET, BY AGE, 2018-2030(USD BILLION) (USD BILLION)
• TABLE 90 JAPAN: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 91 JAPAN: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 92 JAPAN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 93 SOUTH KOREA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 94 SOUTH KOREA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 95 SOUTH KOREA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 96 SOUTH KOREA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 97 SOUTH KOREA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 98 AUSTRALIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 99 AUSTRALIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 100 AUSTRALIA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 101 AUSTRALIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 102 AUSTRALIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 103 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 104 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 105 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 106 REST OF ASIA PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 107 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 108 REST OF THE WORLD: PEG 3350 MARKET, BY COUNTRY, 2018-2030 (USD BILLION)
• TABLE 109 REST OF THE WORLD: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 110 REST OF THE WORLD: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 111 REST OF THE WORLD: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 112 REST OF THE WORLD: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 113 REST OF THE WORLD: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 114 MIDDLE EAST: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 115 MIDDLE EAST: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 116 MIDDLE EAST: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 117 MIDDLE EAST: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 118 MIDDLE EAST: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 119 AFRICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 120 AFRICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 121 AFRICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 122 AFRICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 123 AFRICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 124 LATIN AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 125 LATIN AMERICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 126 LATIN AMERICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 127 LATIN AMERICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 128 LATIN AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 129 MAJOR PLAYERS IN THE GLOBAL PEG 3350 MARKET
• TABLE 130 MOST ACTIVE PLAYER IN THE GLOBAL PEG 3350 MARKET
• TABLE 131 PRODUCT LAUNCH/PRODUCT APPROVAL
• TABLE 132 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 133 LGM PHARMA: PRODUCTS/SERVICES OFFERED
• TABLE 134 MCKESSON CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 135 SISCO RESEARCH LABORATORIES PVT. LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 136 BASF SE: PRODUCTS/SERVICES OFFERED
• TABLE 137 MERCK KGAA: PRODUCTS OFFERED
• TABLE 138 BAYER AG: PRODUCTS OFFERED
• TABLE 139 BAYER AG: KEY DEVELOPMENTS
• TABLE 140 LUPIN PHARMACEUTICALS, INC.: PRODUCTS OFFERED
• TABLE 141 BRECKENRIDGE PHARMACEUTICAL, INC.: PRODUCTS OFFERED
• TABLE 142 PENDOPHARM: PRODUCTS OFFERED
• TABLE 143 PENDOPHARM: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL PEG 3350 MARKET
• FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PEG 3350 MARKET
• FIGURE 5 DRIVER IMPACT ANALYSIS
• FIGURE 6 RESTRAINT IMPACT ANALYSIS
• FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL PEG 3350 MARKET
• FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEG 3350 MARKET
• FIGURE 9 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2022 & 2032 (USD BILLION)
• FIGURE 10 GLOBAL PEG 3350 MARKET, BY AGE, 2022 & 2032 (USD BILLION)
• FIGURE 11 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)
• FIGURE 12 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)
• FIGURE 13 GLOBAL: PEG 3350 MARKET, BY REGION 2022 & 2032 (USD BILLION)
• FIGURE 14 GLOBAL: PEG 3350 MARKET SHARE (%), BY REGION,
• FIGURE 15 NORTH AMERICA: PEG 3350 MARKET SHARE (%), BY COUNTRY
• FIGURE 16 EUROPE: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 17 ASIA-PACIFIC: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 18 REST OF THE WORLD: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL PEG 3350 MARKET
• FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 22 MCKESSON CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 23 MCKESSON CORPORATION: SWOT ANALYSIS
• FIGURE 24 BASF SE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 25 BASF SE: SWOT ANALYSIS
• FIGURE 26 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 MERCK KGAA: SWOT ANALYSIS
• FIGURE 28 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 BAYER AG: SWOT ANALYSIS
• FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS

Global PEG 3350 Market Research Report Information by Product Type (Powder, Bowel Preparation Kit) by Age (Pediatric, Adult, and Geriatric) by Application (Constipation, Medical Tests, [Colonoscopy and Barium Enema X-Ray Examination], and Surgery) by Distribution Channel (Online Pharmacy, Offline Pharmacy), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

In 2023, the market size of PEG 3350 was estimated to be USD 1.92 billion. During the forecast period (2024-2032), the PEG 3350 Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.63%, increasing from USD 2.08 billion in 2024 to USD 3.71 billion by 2032. The market growth is being driven by the increasing prevalence of colon cancer in India and other developing nations, the increasing number of strategic initiatives, and the increasing sedentary lifestyle and physical inactivity.

Colon cancer is becoming more prevalent on a global scale. For example, the Lancet Regional Health Southeast Asia article indicates that colorectal cancer is the seventh most prevalent cancer in India, with 65,358 new cases in 2021. The global incidence of colon cancer has been on the rise, with a current rate of 19.5 per 100,000 population and 15.2 per 100,000 population in India. In the same vein, the evolving lifestyles that encompass the consumption of calorie-rich and low-fiber diets, the excessive consumption of red meat and processed foods, and physical inactivity. Additionally, the age-sex-adjusted rates of colon cancer in India have increased by 20.6%, with a significant increase in the number of adults under the age of 50.

Consequently, the demand for PEG 3350 is expected to rise in response to the increasing prevalence of colon cancer. The PEG 3350 markets are anticipated to be driven by the cumulative prevalence of colon cancer, as well as changing lifestyle habits, including the increasing consumption of alcohol and tobacco products, the rising rates of smoking, and poor dietary habits among the population, during the forecast period.

Market Segment Insights

Powder and digestive preparation kit-based market segmentation for the PEG 3350.

Age is the basis for market segmentation, which encompasses pediatric, adult, and geriatric categories.

The PEG 3350 Market segmentation is determined by the application, which encompasses medical tests and constipation. and surgery.

The market segmentation is determined by the distribution channels, which encompass both online and offline pharmacies.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the North American PEG 3350 market held the highest market share. This is a result of the increasing prevalence of colorectal cancer and other diseases, including diabetes, cancer, and neurological disorders, in the North American region.

The second-largest market share in the Europe PEG 3350 market is attributed to the increasing prevalence of colorectal cancer and the increasing adoption of a sedentary lifestyle throughout the region. In addition, the German PEG 3350 Market was identified as the greatest market share and is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific PEG 3350 market will experience substantial growth from 2024 to 2032. This is a result of the increasing prevalence of colorectal cancer in the Asia-Pacific region, the adoption of sedentary lifestyles and physical inactivity, and the growing geriatric population. Additionally, it is anticipated that the China PEG 3350 Market will possess the highest market share, while India is anticipated to follow suit. The PEG 3350 Market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. The PEG 3350 Market in the regions is expected to experience growth as a result of the lack of awareness associated with the appropriate diet. Additionally, the research indicates that colorectal cancer is on the rise in the Middle East among young and older individuals, and it is a primary cause of frequent constipation in children, which is further contributing to the region's market growth.

Major Players

Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) are among the key companies in the PEG 3350 Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF COLON CANCER IN INDIA AND OTHER DEVELOPING NATIONS
  • 4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
  • 4.2.3 INCREASING SEDENTARY LIFESTYLE AND PHYSICAL INACTIVITY
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS ASSOCIATED WITH PEG
  • 4.3.2 INCREASING PREFERENCE FOR ORGANIC ALTERNATIVES
• 4.4 OPPORTUNITIES
  • 4.4.1 ENTERING DEVELOPING MARKETS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION
  • 5.1.4 MARKETING & SALES
  • 5.1.5 POST-SALES REVIEW/MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL PEG 3350 MARKET
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 POWDER
• 6.3 BOWEL PREPARATION KIT

7 GLOBAL PEG 3350 MARKET, BY AGE

• 7.1 OVERVIEW
• 7.2 PEDIATRIC
• 7.3 ADULT
• 7.4 GERIATRIC

8 GLOBAL PEG 3350 MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 CONSTIPATION
• 8.3 MEDICAL TESTS
  • 8.3.1 COLONOSCOPY
  • 8.3.2 BARIUM ENEMA X-RAY EXAMINATION
• 8.4 SURGERY

9 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL

• 9.1 OVERVIEW
• 9.2 ONLINE PHARMACY
• 9.3 OFFLINE PHARMACY

10 GLOBAL PEG 3350 MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 CHINA
  • 10.4.2 INDIA
  • 10.4.3 JAPAN
  • 10.4.4 SOUTH KOREA
  • 10.4.5 AUSTRALIA
  • 10.4.6 REST OF ASIA-PACIFIC
• 10.5 REST OF THE WORLD
  • 10.5.1 MIDDLE EAST
  • 10.5.2 AFRICA
  • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 COMPETITIVE BENCHMARKING
• 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PEG 3350 MARKET
• 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PEG 3350 MARKET
• 11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL

12 COMPANY PROFILES

• 12.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL ANALYSIS
  • 12.1.3 PRODUCTS/SERVICES OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 KEY STRATEGIES
• 12.2 LGM PHARMA
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS/SERVICES OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 KEY STRATEGIES
• 12.3 MCKESSON CORPORATION
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS/SERVICES OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 SWOT ANALYSIS
  • 12.3.6 KEY STRATEGIES
• 12.4 SISCO RESEARCH LABORATORIES PVT. LTD.
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS/SERVICES OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 KEY STRATEGIES
• 12.5 BASF SE
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS/SERVICES OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 MERCK KGAA
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGIES
• 12.7 BAYER AG
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 LUPIN PHARMACEUTICALS, INC.
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 BRECKENRIDGE PHARMACEUTICAL, INC.
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 KEY STRATEGIES
• 12.10 PENDOPHARM
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 APPENDIX

• 13.1 REFERENCES
• 13.2 RELATED REPORTS